Cargando…

One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial

BACKGROUND: Binostril endoscopic transsphenoidal approach (BETA) is the most used approach for sellar lesions nowadays, while its damage to the nasal structures may cause nasal discomfort and affect nasal functions including respiration and olfaction. With the purpose to improve the post-operative s...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Junhao, Wen, Guodao, Tang, Chao, Cong, Zixiang, Cai, Xiangming, Yang, Jin, Ma, Chiyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632956/
https://www.ncbi.nlm.nih.gov/pubmed/36338620
http://dx.doi.org/10.3389/fsurg.2022.1007883
_version_ 1784824154510327808
author Zhu, Junhao
Wen, Guodao
Tang, Chao
Cong, Zixiang
Cai, Xiangming
Yang, Jin
Ma, Chiyuan
author_facet Zhu, Junhao
Wen, Guodao
Tang, Chao
Cong, Zixiang
Cai, Xiangming
Yang, Jin
Ma, Chiyuan
author_sort Zhu, Junhao
collection PubMed
description BACKGROUND: Binostril endoscopic transsphenoidal approach (BETA) is the most used approach for sellar lesions nowadays, while its damage to the nasal structures may cause nasal discomfort and affect nasal functions including respiration and olfaction. With the purpose to improve the post-operative sinonasal quality of life (QoL), we introduced the one-and-a-half nostril endoscopic transsphenoidal approach (OETA) in 2016 which preserved more natural structures and registered a prospective randomized controlled trial (ChiCTR-IOR-16008222) to compare the two approaches regarding the surgical outcomes and complications. METHODS: Sixty patients with pituitary adenomas were recruited and randomly assigned to the OETA group and the BETA group between April 2016 and May 2017 in Jinling Hospital. The tumor resection rate, endocrinal and visual outcomes, and surgical complications between the OETA and BETA groups were analyzed. Besides, the questionnaire Anterior Skull Base Nasal Inventory-12 (ASK Nasal-12) was used to evaluate patients’ sinonasal QoL at seven time points (pre-operative; 2-weeks, 1-month, 3-months, 6-months, 12-months, and long-term post-operatively). The Sniffin’ Sticks were used to assess patients’ olfactory function objectively in a long term. Each patient was followed for at least 12 months post-operatively. RESULTS: There was no significant difference in tumor resection rate, hormonal and visual outcomes, and surgical complications between the two groups. Regarding the ASK Nasal-12, patients in the OETA group complained less about dried nasal material at 2 weeks after surgery (P = 0.017). One month after surgery, the OETA group had better olfaction function (P = 0.019) compared with the BETA group. However, there was no significant difference in early and long-term postoperative sinonasal QoL between the two approaches according to the entire ASK Nasal-12 metric. The results of the Sniffin’ Sticks showed that the two groups had a similar olfactory performance at long-time follow-up. CONCLUSION: In this single tertiary center trial, the results showed that the OETA achieved the same surgical outcomes and post-operative sinonasal QoL as the BETA. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=13852, identifier: ChiCTR-IOR-16008222
format Online
Article
Text
id pubmed-9632956
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-96329562022-11-04 One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial Zhu, Junhao Wen, Guodao Tang, Chao Cong, Zixiang Cai, Xiangming Yang, Jin Ma, Chiyuan Front Surg Surgery BACKGROUND: Binostril endoscopic transsphenoidal approach (BETA) is the most used approach for sellar lesions nowadays, while its damage to the nasal structures may cause nasal discomfort and affect nasal functions including respiration and olfaction. With the purpose to improve the post-operative sinonasal quality of life (QoL), we introduced the one-and-a-half nostril endoscopic transsphenoidal approach (OETA) in 2016 which preserved more natural structures and registered a prospective randomized controlled trial (ChiCTR-IOR-16008222) to compare the two approaches regarding the surgical outcomes and complications. METHODS: Sixty patients with pituitary adenomas were recruited and randomly assigned to the OETA group and the BETA group between April 2016 and May 2017 in Jinling Hospital. The tumor resection rate, endocrinal and visual outcomes, and surgical complications between the OETA and BETA groups were analyzed. Besides, the questionnaire Anterior Skull Base Nasal Inventory-12 (ASK Nasal-12) was used to evaluate patients’ sinonasal QoL at seven time points (pre-operative; 2-weeks, 1-month, 3-months, 6-months, 12-months, and long-term post-operatively). The Sniffin’ Sticks were used to assess patients’ olfactory function objectively in a long term. Each patient was followed for at least 12 months post-operatively. RESULTS: There was no significant difference in tumor resection rate, hormonal and visual outcomes, and surgical complications between the two groups. Regarding the ASK Nasal-12, patients in the OETA group complained less about dried nasal material at 2 weeks after surgery (P = 0.017). One month after surgery, the OETA group had better olfaction function (P = 0.019) compared with the BETA group. However, there was no significant difference in early and long-term postoperative sinonasal QoL between the two approaches according to the entire ASK Nasal-12 metric. The results of the Sniffin’ Sticks showed that the two groups had a similar olfactory performance at long-time follow-up. CONCLUSION: In this single tertiary center trial, the results showed that the OETA achieved the same surgical outcomes and post-operative sinonasal QoL as the BETA. CLINICAL TRIAL REGISTRATION: http://www.chictr.org.cn/showproj.aspx?proj=13852, identifier: ChiCTR-IOR-16008222 Frontiers Media S.A. 2022-09-23 /pmc/articles/PMC9632956/ /pubmed/36338620 http://dx.doi.org/10.3389/fsurg.2022.1007883 Text en © 2022 Zhu, Wen, Tang, Cong, Cai, Yang and Ma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Surgery
Zhu, Junhao
Wen, Guodao
Tang, Chao
Cong, Zixiang
Cai, Xiangming
Yang, Jin
Ma, Chiyuan
One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title_full One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title_fullStr One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title_full_unstemmed One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title_short One-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: A prospective randomized controlled trial
title_sort one-and-a-half nostril versus binostril endoscopic transsphenoidal approach to the pituitary adenomas: a prospective randomized controlled trial
topic Surgery
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632956/
https://www.ncbi.nlm.nih.gov/pubmed/36338620
http://dx.doi.org/10.3389/fsurg.2022.1007883
work_keys_str_mv AT zhujunhao oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT wenguodao oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT tangchao oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT congzixiang oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT caixiangming oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT yangjin oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial
AT machiyuan oneandahalfnostrilversusbinostrilendoscopictranssphenoidalapproachtothepituitaryadenomasaprospectiverandomizedcontrolledtrial